Format

Send to

Choose Destination
Rheumatol Int. 2018 Jun;38(6):1161-1162. doi: 10.1007/s00296-018-4007-3. Epub 2018 Mar 15.

Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on "Variability of denosumab densitometric response in postmenopausal osteoporosis".

Author information

1
Rheumatology Department, Hospital Sant Joan Despí Moisès Broggi-General Hospitalet, Sant Joan Despí, Spain. vtorrente@csap.cat.
2
Rheumatology Department, Hospital Comarcal Alt Penedès, C/ De l'Espirall, s/n, 08720, Vilafranca del Penedès, Spain. vtorrente@csap.cat.
3
Rheumatology Department, Hospital Sant Joan Despí Moisès Broggi-General Hospitalet, Sant Joan Despí, Spain.

Abstract

We aim to confirm previous observations among postmenopausal osteoporotic women who received denosumab in terms of densitometric changes. We performed an observational clinical practice scenario study assessing baseline bone mineral density and its change after 2 years of treatment in postmenopausal osteoporotic women. Most of our patients were severe and had previous fracture and had received several treatments before denosumab initiation. We observed a 10.06% (± 3.46) improvement in spine, and a 4.87% (± 4.78) improvement in femoral neck. Our findings are in accordance with other authors that suggest denosumab provides densitometric gain in clinical practice in severe postmenopausal osteoporotic women.

KEYWORDS:

Bone mineral density; Denosumab; Osteoporosis

PMID:
29546636
DOI:
10.1007/s00296-018-4007-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center